AstraZeneca Invests $50 Billion in the USA Amid Rising Sales

• AstraZeneca announced an investment of $50 billion in the USA.
• The company's sales increased by 11% due to rising demand for cancer treatment drugs.
• The new plant in Virginia will be the largest single investment in AstraZeneca's history.

AstraZeneca has announced an increase in sales, particularly due to rising demand for cancer treatment medications. In the first half of 2025, the company secured a total revenue of $28 billion in the USA, which is 11% higher compared to the same period last year.

The company also announced an investment of $50 billion in the USA over the next five years. These funds will be directed towards the construction of a new manufacturing plant in Virginia, which will become the largest single investment in manufacturing in the company's history.

AstraZeneca's CEO Pascal Soriot emphasized the importance of the USA for the company and stated that the new plant will produce medical devices for weight control.

Soriot also noted that the company does not plan to request any waivers from the Trump administration regarding investment. AstraZeneca aims to achieve revenues of $80 billion by 2030, half of which may come from the USA.

At the same time, the company does not expect to be impacted by potential tariffs on pharmaceutical products, despite Trump's threats of a 200% tariff on products manufactured outside the USA.

Overall, AstraZeneca continues to expand manufacturing in the USA, planning to fully meet the needs of American patients within a few months.

Tags: USA/Economy